<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716742</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2</org_study_id>
    <nct_id>NCT00716742</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal
      clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each
      follow-up visit (follow-up visits are variable as per physician discretion) and at final
      follow-up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year</measure>
    <time_frame>Baseline, 1 Year</time_frame>
    <description>Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1099</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%</intervention_name>
    <description>1 drop in eye(s) every evening</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lumigan®</other_name>
    <other_name>Xalatan®</other_name>
    <other_name>Travatan®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients can be either: (a) newly diagnosed and require, in the judgment of the treating
        physician, one of study agents as first-line treatment, (b) have an insufficiently
        controlled IOP on their current medication (any but not more than two in combination), and
        a treatment switch to one of study agents is an acceptable option.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR
             presenting with insufficiently controlled IOP on current medication (in the opinion of
             the treating physician)

          -  Patient is having both eyes treated

        Exclusion Criteria:

          -  Contraindications per product labelling will apply.

          -  Patients with any ophthalmic co-morbidity with an influence on visual field
             deterioration or optic nerve head damage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <results_first_submitted>November 30, 2011</results_first_submitted>
  <results_first_submitted_qc>November 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2012</results_first_posted>
  <last_update_submitted>November 30, 2011</last_update_submitted>
  <last_update_submitted_qc>November 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lumigan®</title>
          <description>bimatoprost 0.03%</description>
        </group>
        <group group_id="P2">
          <title>Travatan®</title>
          <description>travoprost 0.004%</description>
        </group>
        <group group_id="P3">
          <title>Xalatan®</title>
          <description>latanoprost 0.005%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="370"/>
                <participants group_id="P3" count="365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="356"/>
                <participants group_id="P3" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>1 Year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="356"/>
                <participants group_id="P3" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="200"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2 Year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3 Year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lumigan®</title>
          <description>bimatoprost 0.03%</description>
        </group>
        <group group_id="B2">
          <title>Travatan®</title>
          <description>travoprost 0.004%</description>
        </group>
        <group group_id="B3">
          <title>Xalatan®</title>
          <description>latanoprost 0.005%</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="364"/>
            <count group_id="B2" value="370"/>
            <count group_id="B3" value="365"/>
            <count group_id="B4" value="1099"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" lower_limit="21" upper_limit="97"/>
                    <measurement group_id="B2" value="67.0" lower_limit="32" upper_limit="98"/>
                    <measurement group_id="B3" value="67.0" lower_limit="23" upper_limit="95"/>
                    <measurement group_id="B4" value="67.0" lower_limit="21" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year</title>
        <description>Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).</description>
        <time_frame>Baseline, 1 Year</time_frame>
        <population>Intent-to-treat, which includes all patients who started the study and completed the one-year follow-up visit and whose data was available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lumigan®</title>
            <description>bimatoprost 0.03%</description>
          </group>
          <group group_id="O2">
            <title>Travatan®</title>
            <description>travoprost 0.004%</description>
          </group>
          <group group_id="O3">
            <title>Xalatan®</title>
            <description>latanoprost 0.005%</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year</title>
          <description>Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).</description>
          <population>Intent-to-treat, which includes all patients who started the study and completed the one-year follow-up visit and whose data was available for this outcome measure.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="5.2"/>
                    <measurement group_id="O2" value="20.3" spread="5.0"/>
                    <measurement group_id="O3" value="20.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="3.3"/>
                    <measurement group_id="O2" value="-4.3" spread="2.7"/>
                    <measurement group_id="O3" value="-4.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lumigan®</title>
          <description>bimatoprost 0.03%</description>
        </group>
        <group group_id="E2">
          <title>Travatan®</title>
          <description>travoprost 0.004%</description>
        </group>
        <group group_id="E3">
          <title>Xalatan®</title>
          <description>latanoprost 0.005%</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Causes of Death not specified</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data for 2-year and 3-year follow-up not interpretable due to extremely high drop out rates.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President, Global Health Outcomes Strategy and Research</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

